Meghanath Yenni/LinkedIn
Aug 4, 2026, 17:03
Meghanath Yenni: Anticoagulant Reversal in Clinical Practice
Meghanath Yenni, Consultant Physician at Medicover Hospitals, shared a post on LinkedIn:
”Anticoagulant Reversal in Clinical Practice:
As anticoagulant use continues to increase, clinicians are encountering more patients with major bleeding, intracranial hemorrhage, and urgent procedures requiring rapid reversal.
A recent 2026 New England Journal of Medicine review provides a practical, evidence-based update on the currently available antidotes and how they should be used.
- Reserve reversal agents for life-threatening or uncontrolled bleeding, or when emergency surgery cannot be delayed.
- Warfarin: Rapid reversal requires IV vitamin K plus 4-factor prothrombin complex concentrate (4F-PCC).
- Unfractionated heparin: Protamine remains the antidote of choice. It partially reverses LMWH and has no effect on fondaparinux.
- Dabigatran: Idarucizumab provides rapid, specific reversal, although delayed dabigatran rebound may occur in some patients.
- Factor Xa inhibitors (apixaban/rivaroxaban): Andexanet alfa provides targeted reversal in carefully selected patients but should be used judiciously because of thrombotic risk, cost, and limited indications. 4F-PCC remains the most widely used nonspecific alternative when andexanet is unavailable or unsuitable.
Before administering any antidote, ask four essential questions:
- Is the bleeding truly life-threatening?
- Is clinically significant anticoagulant still present?
- Can the procedure safely be delayed?
- Does the patient’s thrombotic risk outweigh the benefit of reversal?
As newer anticoagulants become increasingly common, understanding when—and when not—to reverse anticoagulation is becoming just as important as knowing which antidote to use.”

Stay updated with Hemostasis Today.
-
Nov 14, 2026, 00:23Saji Kumar: The Role of Agentic AI in Blood Bank Inventory Coordination
-
Nov 14, 2026, 00:04Carlos A. Metidieri Menegozzo: The First Priority in Trauma Transfusion May Be Time to First Blood Product
-
Nov 13, 2026, 23:43Alamgir Hosen Ronit: Corrected Platelet Count in EDTA Induced Platelet Aggregation
-
Nov 13, 2026, 23:32Evi Loos: Can PRP Improve Pain in Thumb Base Osteoarthritis?
-
Nov 13, 2026, 23:10Cesar de Almeida Neto: Digital Connectivity Can Transform Plateletpheresis Practice
-
Nov 13, 2026, 23:10Chien-Wen Liew: Where PRP Actually Sits in the Evidence
-
Nov 13, 2026, 23:08Erika Koppers: Continuing the Collaborative Journey Towards Equitable Haemophilia Care in South Africa
-
Nov 13, 2026, 23:06Büşra Ece Günaydın: A New Approach to Factor VIII Gene Insertion for Hemophilia A
-
Nov 13, 2026, 22:57Rolf Bekendam: Moderating a Conversation With Experts on Rare Bleeding Disorders